Search Results - "Gregori, Joaquín Gavilá"

SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022) by Ayala de la Peña, Francisco, Antolín Novoa, Silvia, Gavilá Gregori, Joaquín, González Cortijo, Lucía, Henao Carrasco, Fernando, Martínez Martínez, María Teresa, Morales Estévez, Cristina, Stradella, Agostina, Vidal Losada, María Jesús, Ciruelos, Eva

“…Breast cancer is the leading cause of cancer in women in Spain and its annual incidence is rapidly increasing. Thanks to the screening programs in place,…”
Get full text

Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors—Health-EpiGEICAM Study by Lope, Virginia, Guerrero-Zotano, Angel, Ruiz-Moreno, Emma, Bermejo, Begoña, Antolín, Silvia, Montaño, Álvaro, Baena-Cañada, José Manuel, Ramos Vázquez, Manuel, Fernández de Larrea-Baz, Nerea, Chacón, José Ignacio, García-Sáenz, José Angel, Olier, Clara, Muñoz, Montserrat, Antón, Antonio, Sánchez Rovira, Pedro, Arcusa Lanza, Angels, González, Sonia, Oltra, Amparo, Brunet, Joan, Gavilá Gregori, Joaquín, Martínez, María Teresa, Calvo, Lourdes, Rosell, Libertad, Bezares, Susana, Pastor-Barriuso, Roberto, Pérez-Gómez, Beatriz, Martín, Miguel, Pollán, Marina

“…Breast cancer (BC) survivors are advised to follow the WCRF/AICR cancer prevention recommendations, given their high risk of developing a second tumour. We…”
Get full text

Abstract OT1-12-09: Time and motion study of a subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of patients with HER2-positive early breast cancer (PHaTiMa) by Gregori, Joaquín Gavilá, Miranda, Elena López, Escrivá-de-Romaní, Santiago, Rodríguez, Begoña Jiménez, Novoa, Silvia Antolín, Morales, Luis Fernández, Calvo, Elena Galve, Cortijo, Lucía González, Martorell, Antonia Perelló, Ruiz, Julián Lagunar, Santiago, Santiago González

“…Type: Trial in progress. Introduction: Sequential intravenous (IV) treatment with pertuzumab and trastuzumab is effective in disrupting HER2 signalling in…”
Get full text

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial by André, Fabrice, Hee Park, Yeon, Kim, Sung-Bae, Takano, Toshimi, Im, Seock-Ah, Borges, Giuliano, Lima, Joao Paulo, Aksoy, Sercan, Gavila Gregori, Joaquin, De Laurentiis, Michelino, Bianchini, Giampaolo, Roylance, Rebecca, Miyoshi, Yasuo, Armstrong, Anne, Sinha, Rajni, Ruiz Borrego, Manuel, Lim, Elgene, Ettl, Johannes, Yerushalmi, Rinat, Zagouri, Flora, Duhoux, Francois P, Fehm, Tanja, Gambhire, Dhiraj, Cathcart, Jillian, Wu, Cai, Chu, Changan, Egorov, Anton, Krop, Ian

“…In the single-arm, phase 2 DESTINY-Breast01 trial, trastuzumab deruxtecan showed robust activity in patients with HER2-positive metastatic breast cancer who…”
Get full text

Correction: SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022) by Ayala de la Peña, Francisco, Antolín Novoa, Silvia, Gavilá Gregori, Joaquín, González Cortijo, Lucía, Henao Carrasco, Fernando, Martínez Martínez, María Teresa, Morales Estévez, Cristina, Stradella, Agostina, Vidal Losada, María Jesús, Ciruelos, Eva

Get full text

Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists by Sánchez-Rovira, Pedro, Zamora, Pilar, Salvador-Bofill, Javier, Morales, Serafín, Martínez-Jáñez, Noelia, Martínez-de-Dueñas, Eduardo, Lluch, Ana, Illarramendi, José Juan, Gómez-Pardo, Patricia, Gavilá Gregori, Joaquín, García-Palomo, Andrés, García-Mata, Jesús, Fernández, Yolanda, del Barco, Sonia, de Juan, Ana, Ciruelos, Eva, Chacón, José Ignacio, Calvo, Lourdes, Barnadas, Agustí, Albanell, Joan

“…Objective: The aim of this survey conducted by 20 leading Spanish oncologists was to analyze the concurrence between Spanish clinical practice and the recently…”
Get full text

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial by Salvador Bofill, Javier, Moreno Anton, Fernando, Rodriguez Sanchez, Cesar Augusto, Galve Calvo, Elena, Hernando Melia, Cristina, Ciruelos Gil, Eva Maria, Vidal, Maria, Jiménez-Rodriguez, Begoña, De la Cruz Merino, Luis, Martínez Jañez, Noelia, Villanueva Vazquez, Rafael, de Toro Salas, Ruben, Anton Torres, Antonio, Alvarez Lopez, Isabel Manuela, Gavila Gregori, Joaquin, Quiroga Garcia, Vanesa, Vicente Rubio, Elena, De la Haba-Rodriguez, Juan, Gonzalez-Santiago, Santiago, Diaz Fernandez, Nieves, Barnadas Molins, Agusti, Cantos Sanchez de Ibargüen, Blanca, Delgado Mingorance, Juan Ignacio, Bellet Ezquerra, Meritxell, de Casa, Sonia, Gimeno, Asuncion, Martin, Miguel

“…Breast cancer is the most common malignancy and the second leading cause of cancer-related mortality in Spanish women. Ribociclib in combination with endocrine…”
Get full text

Breast cancer in pregnancy: an institutional experience by Blanquisett, Abraham Hernández, Vicent, Carmen Herrero, Gregori, Joaquín Gavilá, Zotano, Ángel Guerrero, Porta, Vicente Guillem, Simón, Amparo Ruiz

“…Breast cancer is one of the most common cancers diagnosed during pregnancy. Pregnancy-associated breast cancer (PABC) is defined as breast cancer diagnosed…”
Get full text

Euthanasia in patients with cancer and the continuous-care providers by Camps Herrero, Carlos, Gavilá Gregori, Joaquín, Garde Noguera, Javier, Caballero Díaz, Cristina, Iranzo González-Cruz, Vega, Juárez Marroquí, Asunción, Safont Aguilera, Maria José, Blasco Cordellat, Ana, Berrocal Jaime, Alfonso, Sanz de Bremond, Maria Godes

“…During the clinical evolution of patients with cancer there are many occasions, or phases of the disease, when there are no specific treatments and, as such,…”
Get full text

Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients by Alberola Candel, Vicente, Carrato Mena, Alfredo, Díaz-Rubio García, Eduardo, Gascón Vilaplana, Pere, González Barón, Manuel, Martín Jiménez, Miguel, Alba Conejo, Emilio, Cassinello Espinosa, Javier, Colomer, Ramon, Cruz Hernández, Juan Jesús, Barnadas i Molins, Agustí, Camps Herrero, Carlos, Casas Fernández de Tejerina, Ana Ma, Carulla Torrent, Joan, Constenla Figueiras, Manuel, Gavilá Gregori, Joaquin, Isla Casado, Ma. Dolores, Massuti Sureda, Bartomeu, Provencio Pulla, Mariano, Rodríguez Sánchez, César Augusto, Sanz Ortiz, Jaime

“…Treatment of anaemia is a very important aspect in the management of cancer patients. In order to carry out a consensus process about the use of erythropoietic…”
Get full text

La eutanasia en el paciente con cáncer y los cuidados continuos by Herrero, Carlos Camps, Gregori, Joaquín Gavilá, Noguera, Javier Garde, Díaz, Cristina Caballero, González-Cruz, Vega Iranzo, Marroquí, Asunción Juárez, Aguilera, Ma José Safont, Cordellat, Ana Blasco, Jaime, Alfonso Berrocal, Bremond, Ma Godes Sanz de

Get full text

Euthanasia in patients with cancer and the continuous-care providers by Camps Herrero, Carlos, Gavilá Gregori, Joaquín, Garde Noguera, Javier, Caballero Díaz, Cristina, Iranzo González-Cruz, Vega, Juárez Marroquí, Asunción, Safont Aguilera, Maria José, Blasco Cordellat, Ana, Berrocal Jaime, Alfonso, Sanz de Bremond, Maria Godes

Get full text

Abstract GS2-01: GS2-01 Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02 by Krop, Ian, Park, Yeon H., Kim, Sung-Bae, Borges, Giuliano, Aksoy, Sercan, Gregori, Joaquin Gavila, Roylance, Rebecca, Lim, Elgene, Yerushalmi, Rinat, Zagouri, Flora, Duhoux, Francois P., Fehm, Tanja, Takano, Toshimi, Egorov, Anton, Wu, Iris, Cathcart, Jillian, Chu, Changan, Andre, Fabrice

“…In DESTINY-Breast01 (NCT03248492) and DESTINY-Breast03 (NCT03529110), trastuzumab deruxtecan (T-DXd) demonstrated unprecedented activity in patients (pts) with…”
Get full text

Abstract PD17-07: Cell-Cycle Inhibition and Immune Microenvironment in HR+/HER2- Breast Cancer During and After preoperative ribociclib and letrozole vesus chemotherapy: A correlative analysis of the 1402-SOLTI/CORALLEEN phase 2 trial by Pascual, Tomás, Chic, Nuria, Fernandez-Martinez, Aranzazu, González-Farré, Blanca, Paré, Laia, Saura, Cristina, Hernando, Cristina, Muñoz, Montserrat, Arumí, Míriam, Galván, Patricia, Gonzalez-Farré, Xavier, Oliveira, Mafalda, Gil, Miguel Gil, Ciruelos, Eva, Villagrasa, Patricia, Gregori, Joaquin Gavila, Prat, Aleix, Perou, Charles M.

“…Background Hormone receptor–positive/HER2-negative (HR+/HER2-) breast cancer (BC) is associated with low % of stromal tumor-infiltrating lymphocytes (sTIL) and…”
Get full text

Abstract P5-19-02: Everolimus in combination with exemestane in hormone receptor-positive locally advanced or metastatic breast cancer (BC) patients progressing on prior non-steroidal AI (NSAIs): Ballet study (CRAD001YIC04) by Jerusalem, Guy, Mariani, Gabriella, Ciruelos, Eva M, Martin, Miguel, Tjan-Heijnen, Vivianne CG, Neven, Patrick, Gavila Gregori, Joaquin, Michelotti, Andrea, Montemurro, Filippo, Lang, Istvan, Mardiak, Josef, Naume, Bjoem, Camozzi, Maura, Lorizzo, Katia, Brenski, Dariusz, Conte, Pierfranco

“…Background: Despite progress, a large number of breast cancer patients experience metastatic relapse and death. Hyperactivation of the mTOR pathway has been…”
Get full text

Everolimus in combination with Exemestane in hormone receptor-positive, locally advanced or metastatic breast cancer patients progressing on prior non-steroidal aromatase inhibitors (NSAIs) : BALLET study (CRAD001YIC04) by JERUSALEM, Guy, Mariani, Gabriella, Ciruelos Gil, Eva M., Martin, Miguel, Tjan-Heijnen, Vivianne CG, Neven, Patrick, Gavila Gregori, Joaquin, Michelotti, Andrea, Montemurro, Filippo, Lang, Istvan, Mardiak, Jozef, Naume, Bjorn, Camozzi, Maura, Lorizzo, Katia, Brenski, Dariusz, Conte, Pierfranco

Get full text